Published in AIDS Weekly, March 10th, 1997
Preliminary results from a Phase I/II trial show that a Ugandan HIV immunoglobulin (Ig) product had no serious toxicity after a single infusion given to mothers at 37-38 weeks' gestation and to infants within their first 16 hours of life.
J.B. Jackson of Johns Hopkins University, Baltimore, Maryland, reported the findings at the Fourth Conference on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.